Prothena Corporation plc (NASDAQ:PRTA) Q4 2021 Earnings Conference Call February 17, 2022 4:30 PM ET Company Participants Jennifer Zibuda - Director-Investor Relations & Communications Gene Kinney - President & Chief Executive Officer Tran Nguyen - Chief Financial Officer & Chief Strategy Officer Hideki Garren - Chief Medical Officer Wagner Zago - Chief Scientific Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Michael Yee - Jefferies Neena Bitritto-Garg - Citi Jay Olson - Oppenheime ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q _____________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30,2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 ______________________________________ PROTHENA CORPORATION PUBLIC LIMITED ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q _____________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 ______________________________________ PROTHENA CORPORATION PUBLIC LIMITED COMP ...

Prothena Corporate Overview May 2021 Forward-Looking Statements 2 This overview contains forward-looking statements. These statements relate to, among other things: the sufficiency of our cash position to fund advancement of a broad pipeline; the continued advancement of our discovery, preclinical and clinical pipeline and expected milestones in 2021 and beyond; our goal of building a protein dysregulation platform; the treatment potential, designs, and proposed mechanisms of action of birtamimab, prasinezu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q _____________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 ______________________________________ PROTHENA CORPORATION PUBLIC LIMITED COM ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-K ______________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35676 ______________________________________ PROTHENA CORPORATIO ...

Prothena Corporation (NASDAQ:PRTA) Q4 2020 Earnings Conference Call February 11, 2021 8:30 AM ET Company Participants Ellen Rose - Head of Communications Gene Kinney - President, Chief Executive Officer & Director Tran Nguyen - Chief Financial Officer & Chief Operating Officer Wagner Zago - Chief Scientific Officer Radhika Tripuraneni - Chief Development Officer Conference Call Participants Jay Olson - Oppenheimer Michael Yee - Jefferies Charles Duncan - Cantor Fitzgerald & Co. Robert Hazlett - BTIG Kennen ...

Prothena Corporate Overview November 17, 2020 Forward-Looking Statements This overview contains forward-looking statements. These statements relate to, among other things: the sufficiency of our cash position to fund advancement of a broad pipeline; the continued advancement of our discovery and preclinical pipeline; our goal of building a neurotherapeutics engine; the design, proposed mechanism of action and possible clinical benefits of prasinezumab (PRX002/RG7935), and its potential as a treatment for Pa ...

Prothena Corporate Overview November 4, 2020 Forward-Looking Statements This overview contains forward-looking statements. These statements relate to, among other things: the sufficiency of our cash position to fund advancement of a broad pipeline; the continued advancement of our discovery and preclinical pipeline; our goal of building a neurotherapeutics engine; the design, proposed mechanism of action and possible clinical benefits of prasinezumab (PRX002/RG7935), and its potential as a treatment for Par ...

Prothena Corporate Overview August 6, 2020 Forward-Looking Statements This overview contains forward-looking statements. These statements relate to, among other things: the sufficiency of our cash position to fund advancement of a broad pipeline; the continued advancement of our discovery and preclinical pipeline; our goal of building a neurotherapeutics engine; the design, proposed mechanism of action and possible clinical benefits of prasinezumab (PRX002/RG7935), and its potential as a treatment for Parki ...